Dasa has chosen to expand upon its partnership with SOPHiA GENETICS SA to offer the first decentralized HRD (Homologous recombination deficiency) analytics solution in Latin America. HRD is a complex biomarker, important for PARP inhibitors, that helps identify whether cancer patients may respond better to specific treatments, and its use could ultimately lead to therapies that benefit the individual patient. Renowned in Brazil and abroad, Dasa serves more than 20 million patients per year – including approximately 10% of the Brazilian population - through its more than 250,000 medical partners comprised of more than 59 diagnostic medicine brands and hospitals. With the help of the knowledge pooling SOPHiA DDM(TM) platform, Dasa has drawn further insights upon the many complex molecular datasets that they analyze for the benefit of their patients. The present announcement further builds on the partnership that began between the two companies in 2016, when Dasa chose SOPHiA GENETICS to build the original workflow for its genomics lab. This partnership further evolved when Dasa implemented SOPHiA DDM(TM) Radiomics and Trial Match solutions in 2020 to create the first multimodal approach in the region. For half a decade, the two companies have pioneered new ways to enable scalability and high output screening on complex assays, shortening the path from research to consumer applications and more.